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Abstract
A recent outbreak of Zika virus has been linked to fetal abnormalities in pregnant women who have been infected.
The scientific community is working toward understanding Zika virus pathogenesis to better manage affected
women and children. In an interview with Dr. Catherine Spong, we discuss the aims and challenges of a
forthcoming longitudinal study of a cohort of pregnant women in areas of current active Zika virus transmission.
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Introduction
Dr. Catherine Spong (Fig. 1) is the Acting Director of the
Eunice Kennedy Shriver National Institute of Child Health
and Human Development at the National Institutes of
Health. In this role, she oversees research on pediatric
health and development, maternal and reproductive
health, intellectual and developmental disabilities, and
rehabilitation medicine, among other areas. Her areas of
expertise include maternal and child health, particularly
prematurity, fetal complications, and improvement of
child health outcomes. Her Institute is currently recruiting
for a multicenter, longitudinal cohort study looking at the
effects of Zika in infants and pregnancy.
1. What do we know so far about Zika virus
infection and pregnancy outcomes?
Zika virus infection in pregnancy has been linked to
adverse complications, including miscarriage, stillbirth,
fetal brain anomalies, and eye disorders. Many questions
about prenatal Zika virus infection remain unanswered.
With the information currently available, we are unable to
inform a woman about the risk to her pregnancy if she is
infected with the Zika virus. We have little information on
how often prenatal Zika infection results in adverse out-
comes such as miscarriage or microcephaly. The current
literature is populated mostly by studies that followed
women who had symptoms of Zika virus infection, such
as rash or fever. Given that an estimated 80 % of people
with Zika virus infection have no symptoms, we need to
conduct studies in this population to understand the risk
of asymptomatic Zika virus infection among pregnant
women. We know that in other infections in pregnancy,
the timing of the infection will help determine the out-
come. The first trimester (weeks 0–13) is commonly
thought to be the most vulnerable period because that is
when most of the organ formation occurs. Some viral in-
fections cause the most damage when the infection occurs
during this time period. However, studies of symptomatic
pregnant women with Zika virus have found that infection
even in the second or third trimesters has resulted in
anomalies in the fetal brain and other serious outcomes,
including stillbirth, which is very concerning.
2. How has NIH responded to this public health
emergency?
The National Institutes of Health (NIH) is very interested
in studying Zika virus and has published two notices
(NOT-AI-16-026 and NOT-HD-16-004) highlighting the
critical areas for research. Notably, we have launched a
rapid solicitation (PAR-16-106) for R21 applications that
allows submissions without preliminary data. The solici-
tation opened on March 20, 2016, and applications are
being accepted on a rolling basis. In my over 20 years of
experience at NICHD, this is the first time I have seen
the use of the rapid funding opportunity announcement,
which is a mechanism that enables continuous receipt
and review of applications and then expedited funding.
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Eight NIH institutes and centers have signed on to this
opportunity: NICHD, the National Institute of Allergy
and Infectious Diseases, the National Institute of Den-
tal and Craniofacial Research, the National Institute
of Neurological Disorders and Stroke, the National Insti-
tute of Mental Health, the National Eye Institute, the Na-
tional Institute of Biomedical Imaging, the National Heart,
Lung, and Blood Institute, and the NIH Division of Pro-
gram Coordination, Planning, and Strategic Initiatives.
Other institutes are likely to join given the multifocal na-
ture of this public health emergency.
NIH’s interest includes basic research to understand
Zika infection pathogenesis and transmission to the
fetus, establishment of animal models to help translate
laboratory findings into living systems, developing diag-
nostics and vaccines, and clinical studies. This clinical
work includes understanding the role of Zika infection
in pregnancy complications, as well as studies of
children and non-pregnant adults to evaluate neurologic
complications such as Guillain–Barre syndrome. I en-
courage wide dissemination of this funding opportunity
to the scientific community.
3. What areas of study do you find most
important in the context of Zika?
We plan to study pregnant women in regions where the
virus is spreading to discern the risk of adverse outcomes
to a woman infected during her pregnancy, whether she is
symptomatic or not. We also want to establish the impact
that the timing of infection has on pregnancy outcomes
and the role, if any, of prior exposures to other pathogens,
such as dengue virus, and to environmental factors such
as pesticides, larvicides, and insect repellents.
Additionally, we want to document the spectrum of
neonatal outcomes related to fetal exposure to Zika virus
infection. This includes not only microcephaly, which has
been reported extensively since the outbreak began, but
also other serious brain anomalies, fetal loss/stillbirth, eye
abnormalities, and developmental and motor outcomes. It
is likely that microcephaly is one of the severe complica-
tions and that more subtle anomalies will be identified
once systematic studies are performed.
4. Who are you recruiting?
We aim to recruit approximately 10,000 pregnant
women at up to 15 sites across Latin America and the
Caribbean, regions currently experiencing active Zika
virus transmission. We anticipate starting recruitment in
early summer. The participants will be in their first tri-
mester, and we will follow them to determine timing of
exposure to Zika virus and whether the women become
symptomatic or not. We will use CDC testing kits to de-
tect Zika infection. However, if new, validated diagnostic
tests become available, we will systematically incorporate
them into the study.
We also want to study the presence of potential con-
founding factors, such as prior infections, including den-
gue and cytomegalovirus, and environmental exposures
to determine what role they may play in the severity of
maternal or infant disease. Our preference is to have pa-
tients enroll as early as possible in pregnancy because
this will improve our ability to evaluate the impact of
the timing of infection on pregnancy outcome.
5. How are you recruiting?
Recruitment will occur through prenatal clinics and
other community outreach, depending on the study site,
region, and country. We recognize that there are
different cultures and methods of providing healthcare
globally, and we will work with local groups to deter-
mine the optimal method for recruitment.
For each site, we will obtain ethics approvals and
participant consent in accordance with local practices.
To participate in this study, all sites will be using the
same methods to gather information and materials, and
the data will be sent to a central location for monitoring
and analysis.
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6. How long do you intend to follow the cohort?
We intend to monitor the women for the duration of
their pregnancies and for 6 weeks after they give birth.
We will follow the infants for up to 2 years after birth. It
will be important for us to follow the children and
mothers after delivery to determine the impact of
prenatal Zika virus infection and to provide sufficient
assessment to document the outcomes. This follow-up
will require clinical examinations, eye exams, imaging
studies, and the collection and analysis of biospecimens.
7. What are the challenges?
Clinical research is inherently challenging. For this
study, we will be challenged by our ability to diagnose
women who are infected with Zika virus – but are
asymptomatic – in areas where dengue virus is also en-
demic. The current diagnostic test for Zika cross-reacts
with dengue virus, and therefore diagnosing Zika infec-
tion may be complicated. In addition, viremia evaluation,
or the presence of virus in the blood, following Zika
exposure may vary between asymptomatic and symp-
tomatic women.
Some women may not want to participate or will
decide to drop out of the study given the concerns and
implications of a Zika diagnosis. Although all studies are
concerned with loss to follow-up or “drop-out”, in this
situation where the visibility is so high and the risks so
personal, it is something we need to watch closely.
Follow-up may be difficult, especially if children have no
signs of abnormalities at birth.
For this study, it will be critically important to have
follow-up of all the children, and not just those with
complications at delivery, to determine the complication
rate and to evaluate brain and developmental milestones.
The concern with losing study participants is the ensu-
ing difficulty of interpreting the study results.
One of the key components of this study is that all
participating sites will use the same protocol, so the
same information will be collected regardless of site or
country. This is essential for us to be able to perform
the analyses and to answer the critical questions. We
have worked very closely with several other groups inter-
ested in studying the impact of Zika virus on pregnancy,
and we have shared our protocol so that they too will
collect information in the same way, enabling us to pos-
sibly collaborate in the future. In addition, we are work-
ing in concert with health agencies in affected countries.
8. Is there anything that the wider scientific
community can do to help with this study?
There has been significant outreach by the research
community. Some groups are making their data available
immediately. One example is the Zika Open Research
portal of O’Connor and Osorio (https://zika.labkey.com/
project/OConnor/ZIKV-001/begin.view). This allows the
community to learn their findings immediately, provides
opportunities for collaboration, and helps others to
generate new research ideas.
We have been working with other groups on the up-
coming cohort study. For example, Fiocruz, a research in-
stitution that is part of the Brazilian Ministry of Health
(http://portal.fiocruz.br/en/content/home-ingl%C3%AAs),
is partnering with NIH on the study by providing scientific
expertise and co-funding some of the sites. We encourage
other groups interested in launching similar studies to
contact us, so we can share information and facilitate po-
tential collaborations.
9. In addition to getting more information to
better manage Zika in pregnancy, are there other
aims of this study?
We need to understand the full impact of the effects of
Zika virus on pregnancy outcomes. A variety of fetal
neurologic abnormalities, such as cerebellar hypoplasia
(the infant’s cerebellum is reduced in size but normal in
shape), global cerebral hypogyration (the folds of the
brain, or gyri, are reduced in number and size), and
intracranial calcifications (calcium deposits in brain
tissue), have already been reported in these children, and
we need a comprehensive evaluation of these cases. We
also need to understand the spectrum of outcomes in
asymptomatic women.
Further, we need better understanding of Zika virus-
related eye and hearing abnormalities, as well as neurobe-
havioral effects such as altered motor function, stiffness,
irritability, and incessant crying. It will be essential to
follow the children after birth to evaluate their neurod-
evelopment and developmental milestones, including chil-
dren who show no signs of anomalies, to fully characterize
the impact of Zika on child health outcomes. Characteriz-
ing the full extent of Zika virus impact on fetal develop-
ment will enable the development of strategies to assess
and monitor the growth of children exposed to the virus
in the womb and to define and optimize ways to treat and
care for these children.
10. Where can I find out more?
See reference list [1–10].
Author’s information
Dr. Spong received her M.D. from the University of Missouri-Kansas City. She
is board-certified in maternal-fetal medicine and obstetrics and gynecology.
She is an editor of many books, including Williams Obstetrics. Her research
awards include the Society for Maternal-Fetal Medicine Achievement Award
and a Surgeon General’s Certificate of Appreciation for her work on
premature birth.
Competing interests
The author declares that she has no competing interests.
Spong BMC Medicine  (2016) 14:84 Page 3 of 4
Received: 18 May 2016 Accepted: 24 May 2016
References
1. Besnard M, Eyrolle-Guignot D, Guillemette-Artur P, Lastère S, Bost-Bezeaud F,
Marcelis L, Abadie V, Garel C, Moutard ML, Jouannic JM, Rozenberg F,
Leparc-Goffart I, Mallet HP. Congenital cerebral malformations and dysfunction
in fetuses and newborns following the 2013 to 2014 Zika virus
epidemic in French Polynesia. Euro Surveill. 2014;2016:21(13).
doi:10.2807/1560-7917.ES.2016.21.13.30181.
2. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P,
Eyrolle-Guignot D, Salje H, Van Kerkhove MD, Abadie V, Garel C, Fontanet A,
Mallet HP. Association between Zika virus and microcephaly in French
Polynesia, 2013–15: a retrospective study. Lancet. 2016.
doi:10.1016/S0140-6736(16)00651-6. Epub ahead of print.
3. Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J, Kolenc M,
Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodušek V, Vizjak A, Pižem J,
Petrovec M, Avšič Županc T. Zika virus associated with microcephaly.
N Engl J Med. 2016;374(10):951–8. doi:10.1056/NEJMoa1600651.
4. Brasil P, Pereira JP Jr, Raja Gabaglia C, Damasceno L, Wakimoto M,
Ribeiro Nogueira RM, Carvalho de Sequeira P, Machado Siqueira A,
Abreu de Carvalho LM, Cotrim da Cunha D, Calvet GA, Neves ES,
Moreira ME, Rodrigues Baião AE, Nassar de Carvalho PR, Janzen C,
Valderramos SG, Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. Zika virus
infection in pregnant women in Rio de Janeiro – preliminary report.
N Engl J Med. 2016. Epub ahead of print. doi:10.1056/NEJMoa1602412.
5. Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, Araujo ES,
de Sequeira PC, de Mendonça MC, de Oliveira L, Tschoeke DA, Schrago CG,
Thompson FL, Brasil P, Dos Santos FB, Nogueira RM, Tanuri A, de Filippis AM.
Detection and sequencing of Zika virus from amniotic fluid of fetuses
with microcephaly in Brazil: a case study. Lancet Infect Dis. 2016.
doi:10.1016/S1473-3099(16)00095-5. Epub ahead of print.
6. Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jääskeläinen AJ, Smura T,
Rosenberg A, Hill DA, DeBiasi RL, Vezina G, Timofeev J, Rodriguez FJ,
Levanov L, Razak J, Iyengar P, Hennenfent A, Kennedy R, Lanciotti R,
du Plessis A, Vapalahti O. Zika virus infection with prolonged maternal
viremia and fetal brain abnormalities. N Engl J Med. 2016. Epub ahead of
print. doi:10.1056/NEJMoa1601824.
7. Hazin AN, Poretti A, Cruz DD, Tenorio M, van der Linden A, Pena LJ, Brito C,
Gil LH, Miranda-Filho DB, Marques ET, Martelli CM, Alves JG, Huisman TA;
Microcephaly Epidemic Research Group. Computed tomographic findings in
microcephaly associated with Zika virus. N Engl J Med. 2016. Epub ahead of
print. doi:10.1056/NEJMc1603617.
8. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and
birth defects - reviewing the evidence for causality. N Engl J Med.
2016;374(20):1981–7.
9. Garcez PP, Loiola EC, Madeiro da Costa R, Higa LM, Trindade P, Delvecchio R,
Nascimento JM, Brindeiro R, Tanuri A, Rehen SK. Zika virus impairs growth in
human neurospheres and brain organoids. Science. 2016;352(6287):816–8.
10. PAR-16-106 – Rapid Assessment of Zika Virus (ZIKV) Complications (R21).
http://grants.nih.gov/grants/guide/pa-files/PAR-16-106.html. Accessed 5/23/2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Spong BMC Medicine  (2016) 14:84 Page 4 of 4
